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Embryonic stem cells are immortalized cells whose proliferation rate is comparable to that of carcinogenic
cells. To study the expression of embryonic stem cell genes in primary cells, genetic screening was performed
by infecting mouse embryonic fibroblasts (MEFs) with a cDNA library from embryonic stem cells. Cold-
inducible RNA-binding protein (CIRP) was identified due to its ability to bypass replicative senescence in
primary cells. CIRP enhanced extracellular signal-regulated kinase 1 and 2 (ERK1/2) phosphorylation, and
treatment with an MEK inhibitor decreased the proliferation caused by CIRP. In contrast to CIRP upregu-
lation, CIRP downregulation decreased cell proliferation and resulted in inhibition of phosphorylated ERK1/2
inhibition. This is the first evidence that ERK1/2 activation, through the same mechanism as that described for
a Val12 mutant K-ras to induce premature senescence, is able to bypass senescence in the absence of p16INK4a,
p21WAF1, and p19ARF upregulation. Moreover, these results show that CIRP functions by stimulating general
protein synthesis with the involvement of the S6 and 4E-BP1 proteins. The overall effect is an increase in kinase
activity of the cyclin D1-CDK4 complex, which is in accordance with the proliferative capacity of CIRP MEFs.
Interestingly, CIRP mRNA and protein were upregulated in a subgroup of cancer patients, a finding that may
be of relevance for cancer research.
Embryonic stem (ES) cells can be propagated indefinitely in
vitro and still maintain their capacity for differentiation into a
wide variety of somatic and extraembryonic tissues (4). A com-
mon characteristic of ES cells and cancer cells is that both are
immortal. When removed from optimal growth conditions, ES
cells will spontaneously differentiate, and the ultimate conse-
quence is a considerably decreased proliferation rate (46, 47).
The possibility that a defective stem cell may be the cause
and origin of cancer is gaining credence since the recent dis-
covery of tissue-specific stem cells (18, 27, 40). In the last
decade, several studies have reported regulatory pathways that
are common to both stem cells and cancer cells; the extent of
this similarity is such that an epigenetic stem cell signature in
cancer has been proposed (54, 59).
Primary mouse embryonic fibroblasts (MEFs) reach replica-
tive senescence after a few passages in culture upon acquisition
of genetic mutations that make them immortal (17). Replica-
tive senescence is characterized by a phenotypic and genotypic
change that results in a loss of proliferative potential (48, 49).
Interestingly, senescent cells have recently been detected in
human tumors, particularly in benign lesions (6, 15); senes-
cence is thus an antitumorigenic mechanism developed by
mammalian cells to avoid cell proliferation when any genetic
alteration has occurred. Genes whose expression bypasses rep-
licative potential are considered candidate oncogenes (13, 22).
The ultimate aim of this study is to identify genes in ES cells
that are implicated in cellular proliferation and that may be
involved in human cancer. If cancer cells mimic the behavior of
ES cells to become immortal, then an examination of ES cell
gene expression may help identify genes that have an impor-
tant function in the process of tumorigenesis.
It has been demonstrated that several proteins detected in
ES cells are overexpressed and promote proliferation in some
types of human cancer (23, 37). This study investigates which
ES cell genes induce proliferation when they are expressed in
primary cells. To this end, a cDNA library of genes expressed
in murine ES cells was overexpressed in primary MEFs, and
then clones with a potentially high proliferative advantage
were selected for further characterization. This led to the iden-
tification of cold-inducible RNA-binding protein (CIRP). A
considerable number of RNA-binding proteins have been
shown to be involved in various diseases, such as congenital
dyskeratosis, cancer, and the genotoxic response (19).
Mammalian cells exposed to mild hypothermia show a gen-
eral inhibition of protein synthesis that is accompanied by an
increase in the expression of a small number of cold-shock
mRNAs and proteins (56). Cold-inducible proteins have been
characterized as sensor proteins whose expression increases in
response to the mild cold stress that is induced by a decrease
in the physiological temperature (37°C) (11). In clinics, hypo-
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thermia is currently employed in both heart and brain surgery
(2, 50); however, the molecular mechanisms regulating the
response to cold stress in mammalian cells is unknown. Apart
from its activation with mild cold induction, CIRP is induced
by hypoxia (57) and has been associated with diurnal changes
in the mouse brain, suggesting a relationship with the regula-
tion of circadian rhythms (36). Therefore, CIRP seems to be a
multifunctional protein that may contribute to the mainte-
nance of normal cell function, apart from the stress response;
however, the precise function of CIRP and its biological role in
cell proliferation are not yet understood.
MATERIALS AND METHODS
Construction of the cDNA library and genome screen. RNA was extracted
from CGR8 and R1 ES cells using TRIzol reagent (Invitrogen SA, Barcelona,
Spain) according to the manufacturer’s instructions. Construction of the library
was performed using a ZAP express cDNA synthesis and cloning kit (Stratagene,
La Jolla, CA). The synthesized cDNAs from CGR8 and R1 ES cells were cloned
into the EcoRI and XhoI sites of the pHygroMaRX vector, as previously de-
scribed (16). The resulting cDNA library contained 6  106 different clones, and
more than 95% of fragments contained a cDNA insert. The MaRX vector
contains two loxP sites flanking the multiple cloning site, which enables gene
excision upon infection with the Cre recombinase. Proliferation screen condi-
tions were based on the clear proliferative effect of a positive control (p53DN)
versus a negative control (green fluorescent protein [GFP]) of proliferation in
primary MEFs, as previously described (22).
Cell culture and infections. CGR8 and E14 ES cell lines were grown in
Dulbecco’s modified Eagle’s medium (DMEM) with 20% serum (HyClone) and
the presence of leukemia inhibitory factor (LGC Promochen). Medium was
changed daily, and cells were not allowed to grow to more than 70% confluence
to avoid spontaneous differentiation. MEFs and HeLa cells were cultured in
DMEM (Lonza, Basel, Switzerland) supplemented with 10% fetal calf serum
(FCS; Lonza) plus antibiotics. Human mammalian epithelial cells (HMECs)
from breast tissue were grown in mammary epithelial cell basal medium plus
supplements (Lonza). TERA cells (human embryonal carcinoma-derived cell
line TERA2) were cultured in DMEM (Gibco) plus 10% FCS, and they were
grown at 10% CO2. MEFs were generated from pregnant mice as previously
described (5). The packaging cell line LinXE was transfected in 10-cm dishes
using the calcium phosphate method with 30 g of library each. Two plates of
negative GFP and positive p53DN controls of proliferation were transfected in
parallel as previously described (16). At 48 h posttransfection, viral supernatants
were collected, filtered, supplemented with 8 g/ml of Polybrene, and used to
infect 10-cm dishes of MEFs at early passage (passage 4 [P4]). After infection,
cells were selected with hygromycin at 50 g/ml (Invitrogen) for 10 days. After
selection, MEFs were seeded at a density of 105 cells per 10-cm plate to allow
proliferative clones to arise. For a scheme of the protocol for performing the
genetic screen and the number of clones obtained, see Fig. S1 in the supplemen-
tal material. Every 2 to 3 days, the medium was changed, allowing proliferative
clones to grow and expand in culture. Finally, two clones were obtained; one
clone was identified as CIRP. The clones that bypassed senescence after being
infected with the library were selected for RNA extraction, cDNA synthesis, and
PCR amplification with specific primers for the MaRx vector. For an example of
the PCR amplification of such clones, see Fig. S2 in the supplemental material.
Sequencing of each PCR product was performed to identify the inserted cDNA
(data not shown). PCR products from the clones that contained a full-length
cDNA were purified, digested with EcoRI and XhoI, and inserted into retroviral
MaRx vectors containing the hygromycin or puromycin resistance genes. In all
the infections, a heterogeneous population resulted after selection of MEFs with
each gene (a GFP, CIRP, p53175H, or Val12 mutant K-ras [K-rasVal12] gene).
All experiments were repeated independently at least three times, each in trip-
licate.
Growth curves. CGR8, HeLa, and primary MEFs were seeded at 1  106 cells
per 10-cm plate. Cells were grown simultaneously, and every 3 days, cells from
each cell line were counted and seeded at a density of 106 cells per dish of the
10-cm plates, as indicated by a 3T3 cell protocol. MEFs at P4 were infected with
GFP-, CIRP-, and p53DN (p53175H)-pII-hygroMaRx and selected over 2 weeks
with hygromycin (50 g/ml; Invitrogen, Carlsbad, CA). After selection, cells were
seeded according to a 3T3 protocol. The relative number of cells is considered as
a measure of the number of cells per passage related to the initial number of cells
seeded per plate.
For the colony formation assay, MEFs were infected with pII-hygro-MaRx-
CIRP or pII-hygro-MaRx-GFP and selected with the appropriate antibiotic.
After selection, 1  105 cells were seeded in triplicate in 10-cm plates and
maintained for 20 days. Finally, cells were fixed and stained with crystal violet for
colony quantification. Senescence-associated -galactosidase activity was ana-
lyzed as previously described (8). Briefly, cells were fixed with 0.5% glutaralde-
hyde, washed in phosphate-buffered saline (PBS; pH 6.0) supplemented with 1 mM
MgCl2, and stained in X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside)
staining solution overnight at 37°C, as specified by the manufacturer (Cell Signaling,
Danvers, MA). The MEK inhibitor PD98058 (Invitrogen) was used at a concentra-
tion of 50 M, and control plates were treated with dimethyl sulfoxide.
Growth in soft agar. To measure the anchorage-independent growth, 1  104
cells were suspended in 1.4% agarose D-1 low electroendosmosis (Pronadisa,
Madrid, Spain) growth medium containing 10% FCS, deposited onto a solidified
base of growth medium containing 2.8% agar (agarose D-1, low electroendos-
mosis; Pronadisa), and overlaid with 1 ml of growth medium. After 24 h, medium
containing 10% FCS was added to each dish and renewed every 2 to 3 days.
Colonies were photographed 3 weeks later. The results were verified in three
independent experiments.
Protein synthesis measurement. Established cell lines of MEFs expressing
CIRP and GFP at P4 were counted and seeded in triplicate wells in 24-well plates
at a density of 105 cells. On the next day, [35S]methionine (Amersham, Buck-
inghamshire, United Kingdom) was added to the culture medium for 2 h at a
final concentration of 5 Ci/ml, as previously described (34). Then, cells were
washed five times with ice-cold PBS and lysed by adding 400 1 of sodium
dodecyl sulfate (SDS) 0.2%. A total of 100 l of ice-cold trichloroacetic acid
([TCA] wt/vol) was added to each well, and the cells were incubated on ice for
30 min. Then, 50 l of lysate was applied to GF/C filters to measure 35S
incorporation by using liquid scintillation spectroscopy. Filters were allowed to
dry and were then washed and boiled in 5% TCA for 2 min; 5% TCA was
replaced, and filters were washed further by boiling them in 5% TCA for an 2
additional min. Finally, they were rinsed in 100% ethanol and allowed to dry
before counting in 3 ml of scintillation liquid. Replicative wells from the same
experiment were harvested simultaneously for both protein determination by
quantifying proteins by Bradford reagent and/or cell number by counting cells
with an inverted microscope using a hemocytometer (viability was determined by
trypan blue exclusion).
Immunoblotting. Total cell lysates were prepared from a confluent 10-cm dish.
Cells were washed in 1 PBS and lysed in 1 ml of lysis buffer (50 mM Tris-HCl,
pH 7.5, 1% NP-40, 10% glycerol, 150 mM NaCl, 2 mM complete protease
inhibitor cocktail; Roche Diagnostics, Barcelona, Spain). At this time, 50 g of
protein from each sample, which had been previously quantified with a Bio-Rad
protein assay (Bio-Rad, Hercules, CA), was electrophoresed on a 10 to 12%
SDS-polyacrylamide gel electrophoresis gel and transferred to a nitrocellulose
membrane. Western analysis was performed as previously described (5) using
antibodies to the following proteins: -actin (Sigma-Aldrich, St. Louis, MO);
cyclin D1 (Neomarkers, Fremont, CA); p53, p21WAF1, p16INK4a, cyclin A2, c-fos,
and total extracellular signal-regulated kinases 1 and 2 (ERK1/2; Santa Cruz
Biotechnology Inc., Santa Cruz, CA); CIRP (Proteintech, Chicago, IL); p19ARF
(Abcam, Cambridge, United Kingdom); and phosphorylated ERK1/2 (P-ERK1/
2), P-MEK1/2, total MEK1/2, S6, S6 phosphorylated at positions 235 and 236
[P-S6 (235/236)], P-S6 (240/244), 4E-BP1 phosphorylated at Thr 37 and 46
[P-4E-BP1 (Thr 37/46)], and 4E-BP1 (Cell Signaling). A rabbit polyclonal anti-
body against CIRP was also generated in our laboratory by immunizing rabbits
with a carboxyl-terminal oligopeptide (DSYDSYATHNE) as previously de-
scribed (35).
Kinase assay. CIRP and GFP MEFs were resuspended in immunoprecipita-
tion buffer (50 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
[HEPES; pH 7.5], 150 mM NaCl, 1 mM EDTA, 2.5 mM ethylene glycol-bis(-
aminoethylether)-N,N,N,N-tetraacetic acid [EGTA], 1 mM dithiothreitol
[DTT], 0.1% Tween 20) containing 10% glycerol, 0.1 mM phenylmethylsulfonyl
fluoride, 10 g of leupeptin per ml, 20 U of aprotinin per ml, 10 mM -glycero-
phosphate, 1 mM NaF, and 0.1 mM sodium orthovanadate (Sigma-Aldrich) and
sonicated at 4°C. Lysates were clarified by centrifugation, and the supernatants
were precipitated for 2 h at 4°C with protein G-Sepharose beads precoated with
saturating amounts of cyclin D1 antibody (Santa Cruz). Immunoprecipitated
proteins on beads were washed four times with 1 ml of immunoprecipitation
buffer and twice with 50 mM HEPES (pH 7.5) containing 1 mM DTT. At this
stage, the supernatant was collected for analysis of -actin by Western blotting as
a loading control for the kinase assay. The beads were resuspended in kinase
buffer (50 mM HEPES, 10 mM MgCl2, 1 mM DTT) containing a substrate pRb
fusion protein (Santa Cruz), 1 g of histone H1 (Roche, Basel, Switzerland), 20
M ATP, and 10 Ci of [-32P]ATP. After incubation for 30 min at 30°C with
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occasional mixing, the samples were boiled in polyacrylamide gel sample buffer
containing SDS and separated by electrophoresis. Phosphorylated proteins were
visualized by autoradiography of the dried gels.
siRNA experiments. MEFs, HMECs, HeLa, and TERA cells were reverse
transfected with 4.4 to 10 l of Hyperfect reagent (Qiagen, Hilden, Germany)
per well of 24-well plates according to maximal transfection efficiency and ab-
sence of toxicity for each cell line. Optimal cell number for transfection was
chosen specifically for each cell line. Transfection optimization was done by using
a final concentration of each small interfering RNA (siRNA) at 30 nM. The
following siRNAs were used: murine CIRP (ID 60854 and ID 160217), human
CIRP (ID 96936 and ID 145723) (Ambion, Austin, TX), a Cy5-labeled siRNA
targeting cyclophilin B (siGLO; Cultek, Landgraaf, The Netherlands) for human
cells and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (AM649; Am-
bion) for murine cells as labeled controls to determine transfection efficiency.
SiGLO and GAPDH controls were chosen because they behaved neutrally in
proliferation after several negative controls for both murine and human cells
were tested. Two independent siRNAs per gene were used. Two days after
transfection, the medium was changed, and cells were maintained for three
additional days. Results were done in triplicate for each siRNA in at least two
independent experiments. Finally, after 5 days of transfection, cell number was
determined by counting cells with an inverted microscope using a hemocytom-
eter (viability was determined by trypan blue exclusion). The absence of apop-
totic cells was verified by analyzing the cell cycle profiles of CIRP siRNA-
transfected cells and comparing them to the profile of our control siRNA (data
not shown).
Real-time PCR. Quantitative real-time TaqMan reverse transcription-PCR
was used to determine the differential expression of CIRP mRNA and the
housekeeping controls: polymerase 2A (POL2A), -actin, and/or 18S RNA.
Such negative controls, which showed no differences between normal and tumor
tissue, were specifically chosen after an endogenous control array was tested by
using microfluidic cards (data not shown) (Applied Biosystems, Foster City, CA).
Relative quantification analysis was performed with an ABI Prism 7700 instru-
ment. The PCR program consisted of denaturing at 95°C for 10 min and 50 cycles
at 95°C for 15 s with annealing and elongation at 60°C for 1 min. Real-time PCRs
were performed in triplicate using Assays-on-Demand TaqMan Gene Expression
Assays (Applied Biosystems) with probes for murine CIRP (Mm01144803_g1) or
human CIRP (Hs00992239_g1). The following probes were used for endogenous
human genes: -actin (Hs99999903_m1), POL2A (Hs00172187_m1), -actin
(Mn00607939_s1) for mouse, and 18S RNA (4310893E) for both species. All
results were validated with at least two different endogenous genes to normalize
variations in cDNA quantities from different samples.
Patient samples. Normal tissue and tumor tissue from 31 patients with colon
carcinoma and 19 patients with prostate carcinoma were randomly chosen from
the tumor bank at the Pathology Department of Vall d’Hebron Hospital (Bar-
celona, Spain). Biopsy samples are routinely collected, quickly frozen, and stored
at 80°C immediately after surgery. All tumors were histologically examined to
confirm the diagnosis of carcinoma. All procedures of the present study have
been approved by the Ethics Committee of Hospital Vall d’Hebron.
Total RNA was extracted from normal and tumor tissue with an RNAeasy
minikit (Qiagen). An RNA Nano Lab Chip kit (Agilent, Palo Alto, CA) was used
to quantify and determine the integrity of the isolated total RNA. cDNA syn-
thesis was performed as previously described (26). Quantitative real-time
TaqMan reverse transcriptase PCR technology (Applied Biosystems) was used to
determine the differential expression of CIRP, POL2A, and 18S RNA. Relative
quantification analysis was performed with the ABI Prism 7700 instrument, and
data were analyzed with sequence detection software (Applied Biosystems). For
protein extracts, to facilitate complete homogenization of the samples, normal
and tumor tissue from each patient was quickly disrupted by using a homogenizer
in protein extraction buffer, following the same protocol as previously described
for cells. Proteins were detected by antibodies for the following: CIRP, -actin,
P-ERK1/2, and ERK1/2. Two different CIRP antibodies were used; one was from
Proteintech, and the other was generated in our laboratory.
TMA. To corroborate the in vitro results, immunohistochemical studies were
performed in the following cancer tissues using a tissue microarray (TMA):
breast (26 infiltrating carcinomas and 7 in situ carcinomas), lung (22 patients),
prostate (9 patients), ovarian (25 patients), colon (17 patients), gastric (19 pa-
tients), skin (13 patients), rhabdomyosarcomas (12 patients), liver and pancreas
(17 patients), nervous system (11 patients), and kidney (15 patients) cancers. The
TMA was constructed by a standard method (41) using cases kindly provided by
the Tumor Bank of the Pathology Department, Hospital Vall d’Hebron. The
cases contained representative samples of the most common tumors. Three-
micrometer tissue sections from the TMA block were sectioned and applied to
special immunohistochemistry coated slides (Dako, Glostrup, Denmark). The
slides were baked overnight in a 56°C oven, deparaffinized in xylene for 20 min,
rehydrated through a graded ethanol series, and washed with PBS. A heat-
induced epitope retrieval step was performed in a solution of sodium citrate
buffer with a pH of 6.5. The slide was then heated for 2 min in a conventional
pressure cooker. After being heated, the slide was incubated with proteinase K
for 10 min and rinsed in cool running water for 5 min. Endogenous peroxide
activity was quenched with 1.5% hydrogen peroxide (Dako) in methanol for 10
min. Incubation with the primary antibodies to CIRP at 1:200 (our antibody) and
P-ERK1/2 (Cell Signaling) at 1:100 was performed. After incubation, immuno-
detection was carried out with the EnVision (Dako) visualization system using
diaminobenzidine chromogen as the substrate, according to manufacturer’s in-
structions. Incubations omitting the primary antibody were used as a control for
this technique (data not shown). All immunostaining was performed in an
BenchMark XT IHQ/ISF Ventana automatic immunostaining device (Roche).
To evaluate immunohistochemical staining, we scored the percentage of positive
cells and intensity of the staining, which was assessed semiquantitatively. Samples
that showed no immunostaining were considered negative, and samples that
showed any positivity were grouped together for statistical purposes. P-ERK1/2
showed three types of positive expression: weak, moderate, or intense. Moderate
to strong positivity was identified easily at low magnification (40), whereas
weak positivity was visible at high magnification (400). Next, CIRP staining was
evaluated. Tumors were considered positive if more than 10% of the cells
showed moderate to strong staining with CIRP antibody.
Statistical analysis. Statistical analysis was performed with the Statistical
Package from Social Science, version 11.5 (SPSS, Inc., Chicago, IL). A Wilcoxon
test was used to compare normal and tumor tissue of all patients with prostate
and colon cancer (colon cancer, P  0.02; prostate cancer, P  0.33). In the
growth curves shown in Fig. 1A and C, 3C, and 6A, a t test has been performed
in order to validate the significance of the data. In addition, a Mann Whitney U
analysis was performed to correlate the expression of CIRP and P-ERK1/2
proteins in each kind of cancer from a total of 193 patients.
RESULTS
CIRP bypasses replicative senescence in MEFs. In order to
compare the proliferation pattern of CGR8, HeLa, and MEFs
cells, a 3T3 protocol was performed (Fig. 1A). Differences
between CGR8 cells and MEFs were statistically significant (t
test, P  0.006). Differences between HeLa cells and MEFs
were also statistically significant (t test, P  0.03). However,
CGR8 grew in a similar fashion to HeLa cells (t test, P 0.15).
These results led to the conclusion that the proliferative ca-
pacity of ES cells and cancer cells is quite similar but markedly
different from that of primary cells (Fig. 1A). Based on this
observation, wild-type MEFs were infected with a mouse em-
bryonic cDNA library in the MaRX retroviral vector to identify
genes involved in proliferation and immortalization. This led
to the finding that the CIRP gene is an immortalizing gene. A
retrovirus-encoded CIRP cDNA conferred unlimited prolifer-
ation capacity on primary MEFs with an efficacy comparable to
that of p53175H (Fig. 1B). While control cells (GFP MEFs)
entered senescence, verification that CIRP bypassed replica-
tive senescence was obtained by the absence of -galactosi-
dase-positive cells in CIRP-expressing MEFs (Fig. 1B). After
infection and subsequent selection, the proliferative function
of CIRP in MEFs was assessed by performing growth curves
following a 3T3 protocol. While GFP MEFs stop growing,
CIRP-expressing cells continue to proliferate (Fig. 1C). Dif-
ferences between CIRP and GFP expression levels were sta-
tistically significant (t test, P  0.04). Moreover, no statistical
differences were obtained in a comparison of CIRP to our
positive control of proliferative p53DN (t test, P  0.85), in-
dicating that CIRP behaves as a true positive control. A char-
acteristic of naïve cells is their low doubling number. Since the
formation of a colony requires several doublings, naïve cells
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will form no colonies or very few colonies. In contrast, immor-
tal cells do not have this limitation. In order to verify that
CIRP MEFs were able to proliferate and form colonies after
being seeded at a low density, a colony formation assay was
performed comparing CIRP and GFP MEFs in parallel to a
positive control of proliferation (p53DN). Interestingly, CIRP
overexpression contributed to the formation of colonies in
MEFs, whereas the control cells (GFP MEFs) did not (Fig.
1D). A quantification of the colony number from two indepen-
dent experiments is shown in Fig. S3 in the supplemental
material. Finally, to verify that the phenotypic effect of CIRP
MEFs was the result of overexpression of CIRP cDNA alone,
coinfection of MEFs was done with CIRP plus an empty vector
and CIRP plus a Cre recombinase cDNA. Proliferation ceased
only when the Cre cDNA was overexpressed (Fig. 1E).
In order to verify CIRP overexpression in our model, CIRP
mRNA was measured by quantitative real-time-PCR (Fig. 2A).
CIRP mRNA was studied in primary MEFs at P2, in senescent
MEFs at P6, and in ES cells. CIRP protein expression was
verified by Western blotting (Fig. 2B) by using two different
antibodies against CIRP. One antibody used was from Protein-
tech, and the other was generated in our laboratory. CIRP
expression was verified in all our experiments at the mRNA
and/or protein level.
CIRP stimulates P-ERK1/2. We investigated the molecular
mechanisms in CIRP MEFs that resulted in maintained growth
under conditions in which senescence occurred in control cells.
This investigation was accomplished by analysis of the status of
the p16INK4a, p19ARF, and p21WAF1 proteins, which have a
known role in the Rb and p53 pathways (51). No differences
were observed in the levels of p16INK4a, p19ARF, or p21WAF1
proteins between GFP and CIRP MEFs after infection and
selection with the appropriate antibiotics at P4 (Fig. 3A). To
verify that p16INK4a, p19ARF, or p21WAF1 was not accumulat-
ing in CIRP MEFs (as they did in GFP MEFs), cells were
analyzed after selection (P4) and during senescence (P6) when
clear phenotypic, -galactosidase-positive cells were present in
GFP MEFs (Fig. 1B). p16INK4a and p21WAF1 clearly accumu-
lated in GFP MEFs at P6 in the presence of -galactosidase-
positive cells, indicating their senescent status (Fig. 1B). How-
ever, this accumulation was not observed in CIRP MEFs at P6
(Fig. 3A). -Actin protein was included as a loading control.
Absence of the above-mentioned accumulated cell cycle-inhib-
itory proteins confirmed the finding that the CIRP gene is an
FIG. 1. CIRP bypasses replicative senescence in primary MEFs. (A) Growth curve of CGR8 ES cells versus HeLa cancer cells or primary MEFs
following a 3T3 protocol. Passage number versus population doublings are represented in the graph. (B) Design of the experimental protocol
performed in MEFs to carry on the genetic screen. -Galactosidase staining was performed in GFP-, CIRP-, and p53DN-expressing MEFs at P6.
Note the presence of -galactosidase-positive cells (blue) only in GFP MEFs and their correlation with the characteristic cell morphology of
senescent cells. (C) Growth curve of MEF cells after infection and selection of the indicated genes after performing a 3T3 protocol. The relative
number of cells is considered a measure of the number of cells per passage relative to the initial number of cells seeded per plate. Negative and
positive controls of proliferation, the GFP and p53DN genes, respectively, were included. (D) Colony formation assay. MEF cells after infection
and selection of the indicated genes were seeded at a density of 105 cells per 10-cm plate and allowed to grow for 15 to 20 days. Finally, they were
stained with crystal violet to observe the colonies formed from individual cells. (E) MEF cells were infected with a retroviral vector carrying CIRP
plus the Cre cDNA or with the empty vector designated S. In parallel, a positive control of proliferation is shown (p53DN).
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immortalizing gene. ERK1/2 activation was measured by levels
of dually phosphorylated ERK1/2 (P-ERK1/2). In contrast,
ERK1/2 activation was observed upon treatment with apop-
totic inducers in CIRP-deficient cells when CIRP was overex-
pressed (44). Hence, the phosphorylation status of the ERK1/2
protein was analyzed in this model. Surprisingly, clear differ-
ences were observed between P-ERK1/2 and total ERK1/2 in
CIRP MEFs and GFP MEFs at P4 (Fig. 3B). The upstream
protein MEK1/2 was also affected (Fig. 3B). Total ERK1/2 and
MEK1/2 were included as protein loading standards for their
respective phosphorylated forms.
Since K-rasVal12 provokes premature entry into senescence
through the activation of P-ERK1/2 (24, 61), verification that
K-rasVal12 MEFs entered premature senescence was per-
formed (Fig. 3C; see also Fig. S4 in the supplemental material).
A t test was performed to validate the results from Fig. 3C.
CIRP MEFs differed significantly from GFP (P  0.01) and
K-rasVal12 (P  0.01) MEFs. In contrast, no statistical differ-
ences were found between GFP and K-rasVal12 MEFs (P 
0.21). It was also verified that K-rasVal12 induced an increase in
P-ERK1/2 at P4 (Fig. 3D). Senescence was also verified by
studying several cell cycle-regulatory proteins in different cell
lines, including CIRP, K-rasVal12, and GFP MEFs. In agree-
ment with previous reports (24, 25, 49), there was a great
increase in p19ARF and p21WAF1 levels in K-rasVal12 MEFs at
the same time that ERK1/2 phosphorylation occurred (Fig.
3D). However, this strong increase did not occur in CIRP or
GFP MEFs at the same passage. Cyclin A2 was also studied as
an indicator of decreased proliferation in primary cells. Its role
as an indicator was previously reported in K-rasVal12 overex-
pression (49). To determine whether the opposing cell re-
sponses mediated by P-ERK1/2 are related to the amount of
active ERK1/2, P-ERK1/2 was quantified and compared in
CIRP, K-rasVal12, and GFP MEFs at P4 (Fig. 3E). ERK1/2
activation was stronger in K-rasVal12 MEFs than in CIRP
MEFs. Based on these observations, it is speculated that both
the intensity and duration of the P-ERK1/2 signal might be
involved in the determination of whether a cell enters into
senescence. Therefore, P-ERK1/2 in CIRP and K-rasVal12
MEFs was analyzed in a later passage than P4 (e.g., P7). As
predicted, P-ERK1/2 activation was maintained in K-rasVal12
MEFs but not in CIRP MEFs (see Fig. S5 in the supplemental
material).
In order to determine how CIRP bypasses replicative senes-
cence, several ERK1/2 substrates have been studied (55). Al-
though no differences in c-myc or p53 status were detected
between CIRP and GFP MEFs (data not shown), c-fos was
upregulated in CIRP MEFs (Fig. 3F). Fos family members
induce cell cycle entry by activating cyclin D1 (3). Therefore,
cyclin D1 was analyzed in CIRP, GFP and K-rasVal12 MEFs.
Interestingly, cyclin D1 was clearly upregulated in CIRP MEFs
compared to GFP MEFs (Fig. 3F). Unexpectedly, cyclin D1
protein was also upregulated in K-rasVal12 MEFs compared to
GFP MEFs at P4 in the concomitant presence of -galactosi-
dase-positive cells (Fig. 3F; see also Fig. S4 in the supplemen-
tal material). A key step required for passage through the G1/S
transition is induction of cyclin D1 and activation of cyclin
D1-CDK4/6 complexes (31). Consistent with the observation
that cyclin D1 was upregulated in CIRP MEFs, kinase activity
assays of cyclin D1-CDK4 complexes demonstrated that the
kinase activity was present in CIRP MEFs while absent in GFP
and K-rasVal12 MEFs. -Actin, which was used as a loading
control, did not vary (Fig. 3G). Thus, cyclin D1-CDK4-associ-
ated kinase activity in CIRP MEFs stimulates progression
through the cell cycle and ultimately activates proliferation. In
order to determine if CIRP overexpression causes a prolifer-
ative effect in cell lines other than MEFs, CIRP was overex-
pressed in the murine immortalized cell line NIH 3T3, the
human cancer cell line HeLa, the human primary cell line
IMR90, and the human primary cell line HMEC. In contrast to
MEF cells, only slight differences were observed in prolifera-
tion when these cells were tested with CIRP overexpression
FIG. 2. CIRP expression in various cell lines. (A) MEF cells were infected with a retroviral vector carrying the indicated genes, selected with
appropriate antibiotics, and after selection were split following a 3T3 protocol. At P6 when clear phenotypic characteristics distinguish GFP- from
CIRP-expressing cells, RNA was extracted to perform quantitative real-time PCR. Primary MEFs at early passage (P2) were also included, and
ES cell lines CGR8 and ROSA 21 are shown as positive controls of CIRP expression as the original cDNA library was from both ES cell lines.
(B) Duplicate dishes from CIRP- and GFP-expressing MEFs were kept for protein extraction. An immunoblot with anti-CIRP antibody is shown
with two independent CIRP antibodies (one from Proteintech and the other generated in our laboratory). -Actin is shown as loading control.
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(data not shown). No differences were observed in the
P-ERK1/2 status of CIRP or GFP cells in any human cell lines
or in NIH 3T3 cells (data not shown).
CIRP increases protein synthesis. The cold-inducible pro-
tein Rbm3, which belongs to the same family as CIRP, has
been shown to increase global protein synthesis by binding to
60S ribosomal subunits (9). Given that a proliferative effect
caused by CIRP was clearly observed in these experiments, the
next study addressed whether general protein synthesis was
also affected. Total protein synthesis production was investi-
gated by measuring 35S methionine incorporation in CIRP,
GFP and K-rasVal12 MEFs (Fig. 4A). The increase in general
protein synthesis production observed in CIRP MEFs led to an
investigation of the proteins involved in controlling the trans-
lational machinery. This included S6 and proteins that regulate
the initiation and elongation phases of translation, such as
4E-BP1. Interestingly, the phosphorylation status of S6 at po-
sitions 235 and 236 was increased in CIRP MEFs compared to
GFP or K-rasVal12 MEFs (Fig. 4B). Moreover, the phosphor-
ylation status of S6 at positions 240 and 244 decreased in
K-rasVal12 MEFs, correlating with their entry into senescence
(Fig. 3C and 4B). Total 4E-BP1 and P-4E-BP1 (Thr 37/46)
were both upregulated in CIRP MEFs compared to GFP and
K-rasVal12 MEFs (Fig. 4C). This rendered the 4E-BP1 protein
inactive and facilitated initiation of translation. eIF-4E protein
did not vary between CIRP MEFs and GFP MEFs (data not
shown). Akt is an upstream protein of S6 which functions in
the phosphatidylinositol 3-kinase pathway but not the mitogen-
activated protein kinase (MAPK) pathway (30). Akt did not
vary between CIRP and GFP (data not shown). This finding
ruled out the possibility that the phosphatidylinositol 3-kinase
pathway could affect the phosphorylation status of S6.
FIG. 3. Cell cycle proteins during senescence. (A) MEF cells were infected with the indicated genes, selected with appropriate antibiotics,
and, after selection, were split following a 3T3 protocol. Immunoblot of CIRP MEFs versus GFP MEFs with antibodies to p16INK4a, p19ARF,
and p21WAF1 at P4 and in later passage when GFP vector-infected cells reached a clear senescence morphology (P6). (B) Immunoblot of
CIRP and GFP MEFs with P-ERK1/2 and P-MEK1/2 antibodies; total ERK1/2 and MEK1/2 are shown as loading controls. (C) Growth curve
of GFP, CIRP, and K-rasVal12 MEFs after following a 3T3 protocol. Cells were counted at different passages, and relative cell numbers are
shown. The relative number of cells is considered a measure of the number of cells per passage relative to the initial number of cells seeded
per plate. (D) Immunoblot of CIRP, GFP, and K-rasVal12 MEFs with antibodies to p21WAF1, p19ARF, p16INK4a, and cyclin A2. Total ERK1/2
is shown as a loading control. (E) P-ERK1/2 quantification versus total ERK1/2 in CIRP and K-rasVal12 MEFs. Results represent the mean
of three independent experiments. (F) Immunoblot of CIRP, GFP, and K-rasVal12 MEFs with antibodies to c-fos and cyclin D1. -Actin is
shown as loading control. (G) Kinase assay in CIRP, K-rasVal12, and GFP MEFs. CIRP MEFs exhibit high kinase activity compared to
senescent cells, either by replicative senescence (GFP) or by oncogene-induced senescence (K-rasVal12). -Actin is shown as a loading control
from the same supernatants of the kinase assay samples. IP, immunoprecipitation; WB, Western blotting.
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In order to test if ERK1/2 activation was responsible for the
proliferative phenotype of CIRP, CIRP and GFP MEFs were
treated daily with the MEK inhibitor PD98058. While PD98058
had no significant effect on GFP MEFs, it did significantly
decrease the proliferative capacity of CIRP MEFs (Fig. 4D
and E). A decrease in P-S6, a decrease in P-4E-BP1, and no
change in c-fos accompanied the decrease in proliferation
(Fig. 4F and G).
CIRP downregulation inhibits proliferation. In order to
study if CIRP inhibition provoked an effect opposite to CIRP
overexpression, an siRNA strategy was used. For this purpose,
two different CIRP siRNAs were tested in different cell lines.
Murine and human siRNAs against CIRP were able to down-
regulate CIRP mRNA and protein (Fig. 5A and data not
shown). Protein extraction of CIRP MEFs transfected with
siRNA against GAPDH was compared to cells transfected with
siRNAs against CIRP using an analysis of P-ERK1/2 status
(Fig. 5A). Interestingly, CIRP inhibition provoked a decrease
in cell number in CIRP MEFs compared to cells with siRNA
against GAPDH (Fig. 5B). The cancer cell line HeLa was also
studied. In this study, CIRP downregulation provoked a de-
crease in cell numbers at different levels (Fig. 5C).
Finally, CIRP was identified from a cDNA library of ES
cells. Using this information, the effect of CIRP on other cells
with ES cell-like properties (i.e., TERA cells derived from
teratocarcinoma) was determined. Interestingly, CIRP down-
regulation decreased the cell number of TERA cells. Figure
5D contains graphs representing counted cell numbers 5 days
after transient transfection of the indicated siRNAs.
Although CIRP decreased cell numbers in HeLa and TERA
FIG. 4. CIRP increases protein synthesis. (A) MEF cells were infected with the indicated genes and selected with appropriate antibiotics. After
selection they were seeded at 105 cells per well in a 24-well plate. The following day, [35S]methionine was added to the culture medium and
incubated for 2 h. The graph shows [35-S]methionine incorporation in CIRP MEFs relative to GFP MEFs as a measurement of general protein
synthesis. (B) MEF cells were infected with the indicated genes and selected with appropriate antibiotics. After selection, protein extracts were
collected for immunoblotting with S6 ribosomal protein and an antibody that recognizes its phosphorylation (P-S6) at positions 235/236 and
240/244. (C) Relative quantification of P-4E-BP1 protein at positions Thr 37/46, total 4E-BP1 in CIRP MEFs, and two negative controls of
proliferative GFP and K-rasVal12 MEFs. Results represent the mean of three independent experiments. The bands of the immunoblot were
quantified by specific software (Quantity One). (D) MEF cells were infected with the indicated genes and selected with appropriate antibiotics.
After selection, they were seeded at 105 cells per well in a 24-well plate. Cell number after treatment of CIRP MEFs compared to GFP MEFs at
P4 with the MEK inhibitor PD98058 for 1 week is shown. (E) The MEK inhibitor PD98058 is able to reverse the proliferative phenotype in CIRP
MEFs, but it does not affect GFP MEFs. (F) MEF cells were infected with CIRP, selected with appropriate antibiotics, and further seeded at a
density of 0.5  106 cells per 10-cm plate. Two plates were treated with PD98058 and compared to control plates (dimethyl sulfoxide [DMSO]).
Protein extracts were collected for immunoblotting of P-ERK1/2, ERK1/2, P-S6 235/236, S6, and c-fos. (G) Relative quantification of P-4E-BP1
protein at positions Thr 37/46 compared to total 4E-BP1 in CIRP MEFs treated with the MEK inhibitor PD98058 from the same experiment as
in panel F. All experiments were performed independently at least two times.
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cells compared to a negative control of proliferation (siGLO),
their P-ERK1/2 status was not affected (data not shown).
CIRP is not involved in transformation. The ability of CIRP
to protect cells against premature senescence induced by K-
rasVal12 was also examined. Wild-type MEFs rapidly arrested
upon infection with a retrovirus-encoded K-rasVal12. Con-
versely, MEFs expressing CIRP (Fig. 6A) in the presence of
K-rasVal12 continued to proliferate. Statistical comparisons
showed that coinfected CIRP and rasVal12 MEFs differ from
coinfected GFP and rasVal12 MEFs (t test, P  0.03). A pre-
vious study proposed that another cold-inducible protein
(Rbm3) belonging to the same family of CIRP should be con-
sidered an oncogenic protein (53). In order to study whether
CIRP could be considered an oncogenic protein, the ability of
CIRP to induce transformation was studied. In this study, the
ability of CIRP to transform cells in cooperation with mutant
K-rasVal12 was examined. K-rasVal12 MEFs are unable to form
colonies in soft agar due to the ability of K-rasVal12 to induce
premature senescence in primary cells. Therefore, the cooper-
ation of oncogenic proteins may provide their ability to form
colonies in the presence of K-rasVal12. These experiments dem-
onstrated that while K-rasVal12 caused neoplastic transforma-
tion of E1a vector-infected cells, K-rasVal12 did not acquire the
ability to form foci or colonies in soft-agar assays in CIRP-
expressing MEFs. Therefore, coexpression of K-rasVal12 and
CIRP did not contribute to transformation in either primary
MEFs or NIH 3T3 immortalized cells (Fig. 6B and data not
shown).
CIRP in human tumors. The next study investigated
whether the CIRP gene had any effect in human tumors by
comparing CIRP mRNA expression in normal and mutant
tissue from the same patient. CIRP mRNA was analyzed by
quantitative real-time PCR in 19 prostate and 31 colon carci-
nomas. Mean values from all patients analyzed are shown in
Fig. 7A and B. CIRP mRNA upregulation was observed in 7 of
19 (36%) prostate and 11 of 31 (35%) colon cancer patients
(Fig. 7C). To confirm CIRP protein upregulation, protein anal-
ysis was performed in four cases in which mRNA was found to
be upregulated. An example of two patients is shown (Fig. 7D).
Statistical analysis showed that in colon carcinomas our results
were significant in comparisons of normal and mutant tissues
(Wilcoxon test, P  0.02). In contrast, our results were not
significant in prostate carcinomas. In order to determine if
CIRP overexpression might be associated with an increase in
P-ERK1/2 status in human tumors, P-ERK1/2 was analyzed in
six patients with colon cancer and two patients with prostate
cancer. P-ERK1/2 was upregulated in three of six samples of
colon cancer and one of two cases of prostate cancer. An
example of four patients is shown in Fig. 7E. In order to
determine if this association was truly significant, we assayed a
FIG. 5. CIRP downregulation in various cell lines. (A) Immunoblot of P-ERK1/2, ERK1/2, and CIRP (our laboratory) from MEF cells
transfected with the CIRP(1) siRNA. (B) MEFs cells at P4 were infected with a vector carrying CIRP cDNA and selected with appropriate
antibiotics. Then, cells were counted and inversely transfected with Hyperfect reagent at a density of 10  103 to 25  103 cells per well in a 24-well
plate. Two different siRNAs against CIRP were used and compared to a neutral siRNA against GAPDH. Cells were counted 5 days after
transfection with an inverted microscope using a hemocytometer (viability determined by trypan blue exclusion). (C) Cell number of HeLa cells
after transient transfection with two different CIRP siRNAs compared to neutral siRNA (siGLO). (D) Cell number of TERA cells after transient
transfection of two different CIRP siRNAs compared to neutral siRNA (siGLO). siRNA results from two independent experiments are shown for
all cell lines.
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larger series of tumors (193 patients). The patients were ana-
lyzed according to cancer type using immunohistochemistry for
CIRP and P-ERK1/2 antibodies. Positive and negative controls
were included for each antibody. P-ERK1/2 was found in both
the nucleus and the cytoplasm, and both types of staining were
considered positive. In contrast, CIRP was expressed mainly in
the cytoplasm. The number of patients staining positive for
either P-ERK1/2 or CIRP in several types of cancer is repre-
sented in Tables 1 and 2, respectively. Interestingly, central
nervous system-related tumors showed a significant correlation
(P  0.05) between P-ERK1/2 and CIRP (Fig. 8A). Results
approached significance in the liver-pancreas carcinomas (Fig.
8A and B).
DISCUSSION
We identified the CIRP gene by exploiting the entry of
MEFs into stress-induced senescence in culture. CIRP over-
expression bypasses replicative senescence in primary MEFs.
CIRP is a cold-inducible member of the glycine-rich RNA-
binding protein family. Although the function of CIRP has not
yet been determined, it has been suggested that this protein
may affect gene expression by facilitating translation at mildly
cold temperatures, such as 32°C (11). We have shown in this
study that CIRP-expressing MEFs at physiological tempera-
ture, in contrast to GFP MEFs, did not overexpress the senes-
cence-associated protein p16INK4a or p21WAF1. Furthermore,
they did not accumulate in -galactosidase-positive cells, which
would indicate senescence.
Interestingly, CIRP expression led to an increase in the
phosphorylation state of MEK1/2 and ERK1/2 kinases.
MAPKs are important mediators of signal transduction from
the cell membrane to the nucleus, and ERK1/2 plays a central
role in cell proliferation control (32). Activation of the ERK
pathway may critically contribute to tumorigenesis or cancer
growth, as seen by the presence of activated ERK1/2 in a
variety of human tumor cell lines and cancer tissues.
The elevated phosphorylation level of ERK1/2 kinase in
CIRP MEFs compared to GFP MEFs is an interesting discov-
ery. ERK1/2 activation has been described in K-rasVal12 cells as
the main cause of premature entry into senescence when it is
overexpressed in primary MEFs (24, 61). Therefore, K-
rasVal12-expressing MEFs were studied in parallel to CIRP and
GFP. In order to unravel the intricate mechanism occurring
downstream of P-ERK1/2 in K-rasVal12 and CIRP MEFs, sev-
eral cell cycle regulatory proteins were studied. These proteins
would explain why some cells entered senescence while other
cells bypassed it. Interestingly, the senescence-associated pro-
teins p16INK4a, p19ARF, and p21WAF1 were highly upregulated
in K-rasVal12 MEFs but not in CIRP MEFs. Although cyclin
D1 was also upregulated in K-rasVal12 MEFs, these data sug-
gest that p19ARF and p21WAF1 stimulation plays a crucial role
in inducing cell arrest and premature senescence. There are
three explanations for these findings: (i) upregulation of
p19ARF and p21WAF1 occurs as early as ERK1/2 activation; (ii)
p19ARF and p21WAF1 activation is about 10-fold stronger than
GFP; (iii) p19ARF and p21WAF1 upregulation correlates with
the presence of -galactosidase-positive cells at P4 (see Fig. S4
in the supplemental material).
Interestingly, our results suggest that although both CIRP
and K-rasVal12 activate the same protein (P-ERK1/2), each of
them shuts down divergent downstream pathways that evolve
into different cellular responses. p19ARF, p21WAF1, and
FIG. 6. CIRP is not involved in transformation. (A) MEF cells were infected with a retroviral vector carrying CIRP and compared to those with
GFP cDNAs. The cells were selected with appropriate antibiotics and coinfected with retroviruses expressing an empty vector (S) or K-rasVal12.
Cells were selected again with appropriate antibiotics. Then, 105 cells were seeded in the wells of 24-well plates and fixed daily for 5 days. Finally,
they were stained with crystal violet and destained with 10% acetic acid. Absorbance measurement at 595 nm was used as an indicator of the
relative number of cells. (B) Soft-agar assay using GFP-rasVal12 and E1a-rasVal12 as negative and positive controls, respectively, of proliferation.
K-rasVal12 does not contribute to transformation in CIRP MEF cells as no clear colonies were observed in medium containing agar.
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p16INK4a prevent cell proliferation in K-rasVal12 MEFs while
immortalization occurs in CIRP MEFs.
In MEFs, CIRP overexpression induces ERK1/2 phosphor-
ylation and proliferation in a manner that seems to be specific
for MEFs. The phosphorylation does not occur in immortal-
ized murine cells or primary and immortalized human cells
(data not shown). This could be explained by the complexity of
primary human cells compared to murine cells. Human cells
may need more than a single event to bypass senescence and
become completely immortalized. Therefore, the molecular
pathways that immortalize human and murine cells do not
necessarily focus on the same target proteins. Overall, it is not
surprising that CIRP overexpression bypasses senescence in
primary murine cells but has no effect on their human coun-
terparts. The fact that CIRP overexpression does not increase
proliferation of NIH 3T3 cells could be explained by the im-
mortalized nature of NIH 3T3 cells. The ability of primary cells
to modulate the expression of certain genes is lost with immor-
FIG. 7. CIRP expression in prostate and colon tumors. (A) Average of mRNA levels quantified by real-time PCR in 19 prostate carcinomas.
N, normal; T, tumor. (B) Average of mRNA levels quantified by real-time PCR in 31 colon carcinomas. (C) Summary of all patients analyzed by
quantitative real-time PCR. (D) Immunoblot of the CIRP protein in two patients with colon carcinoma. A total of 250 g of total protein extract
was used. (E) Example of a P-ERK1/2 immunoblot in four patients where CIRP was upregulated (P3, P4, and P5, patients with colon cancer; P6,
patient with prostate cancer).
TABLE 1. P-ERK1/2 protein expression in human cancer
Cancer type No. of P-ERK1/2-positivepatients
Total no. of
patients
Liver-pancreas 5 17
Gastric 4 19
Nervous system 11 11
Skin 4 13
Lung 1 22
Kidney 2 15
Ovarian 7 25
Rhabdomyosarcomas 5 12
Breast (infiltrating) 7 26
Breast (in situ) 1 7
Colon 4 17
Prostate 0 9
Total 46 193
TABLE 2. CIRP protein expression in human cancer
Cancer type No. of CIRP-positivepatients
Total no. of
patients
Liver-pancreas 6 17
Gastric 9 19
Nervous system 4 11
Skin 0 13
Lung 6 22
Kidney 5 15
Ovarian 3 25
Rhabdomyosarcomas 2 12
Breast (infiltrating) 8 26
Breast (in situ) 3 7
Colon 7 17
Prostate 2 9
Total 55 193
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talization (28). This occurs because a mutation is responsible
for the immortal phenotype (42). How such mutation(s) affect
CIRP downstream pathways should be deeply investigated for
each specific immortalized cell line. In addition, NIH 3T3 cells
proliferate in response to the activation of the ERK pathway
(21). Thus, the fact that P-ERK1/2 is not increased in NIH 3T3
cells upon CIRP overexpression could explain at least in part
their lack of proliferation.
P-ERK1/2 has been proposed to be a master regulator of the
G1/S transition (32). It is puzzling how P-ERK1/2 could func-
tion as a master regulator of cell cycle progression in our
model. It was found that the level of P-ERK1/2 in CIRP MEFs
was approximately half that in K-rasVal12 MEFs. It is hypoth-
esized that the intensity of P-ERK1/2 activation might be im-
portant when the cell shuts down a downstream pathway of
P-ERK1/2 that ends in a different cell response. Moreover, the
fact that P-ERK1/2 is maintained in K-rasVal12 MEFs at P7
suggests that the duration of ERK1/2 signaling might be im-
portant in the maintenance of a senescence phenotype in pri-
mary MEFs (see Fig. S5 in the supplemental material). Our
results support previous studies performed in vivo and in vitro
that describe a dose-dependent oncogene-induced senescence
in different contexts (45).
The presence of proliferative signals downstream of ERK1/2
that could differentiate CIRP from GFP and K-rasVal12 MEFs
was investigated. This investigation was based on the presump-
tion that there is no lack of inhibitory signals in CIRP MEFs
that would explain why they do not enter into senescence.
Several ERK1/2 substrates have been described (55). Among
them, we found the c-fos protein to be upregulated in CIRP
MEFs relative to GFP MEFs. Given the fact that c-fos is a
component of the AP-1 complex and that the cyclin D1 pro-
moter contains a functional AP-1 binding site (52), one possi-
ble mechanism by which the ERK pathway might stimulate
proliferation could be by activating the cyclin D1 protein. In-
terestingly, both the levels of cyclin D1 and its kinase activity
were highly upregulated in CIRP MEFs compared to GFP
MEFs. Although cyclin D1 was also upregulated in K-rasVal12
MEFs, some studies have shown that expression of activated
ras is sufficient to induce an accumulation of cyclin D1 in
several cell types (10, 60). For example, Quereda et al. linked
an increase in cyclin D1 to p21WAF1 in MEFs since cyclin D1
is absent in p21WAF1-deficient MEFs (38).
Our data suggest that a myriad of molecular events take
place upon K-rasVal12 overexpression. Furthermore, the final
cell response is generated by a balance between proliferative
and inhibitory signals. However, the high cyclin D1-CDK4
activity observed in CIRP MEFs suggests that another down-
stream ERK1/2 protein might be separately involved from
c-fos activation.
A major role has been described for the ERK1/2 pathway in
neuronal activity-induced phosphorylation of S6, eIF-4E, and
4E-BP1. This phosphorylation occurs in long-lasting forms of
synaptic plasticity and memory, linking the ERK pathway to
proteins that regulate translational machinery (20). The in-
crease in total protein synthesis observed in CIRP MEFs com-
pared to GFP MEFs prompted a study of translation-related
proteins. Our results demonstrated an association between
CIRP and an increase in total protein synthesis. These findings
agree with a previous study that shows that Rbm3, another
RNA-binding protein, increases protein synthesis in a different
model of immortalized N2a cells (9). Further studies have
shown the ability of Rbm3 to act as an oncogene (53). There-
fore, we hypothesize that any of these proteins (S6, 4E-BP1, or
eIF-4E) could be considered a candidate target for cyclin D1
induction of associated kinase activity in CIRP MEFs.
FIG. 8. Concomitant CIRP and P-ERK expression in human tumors. (A) A Mann-Whitney U test was used to validate the correlation of CIRP
and P-ERK1/2 proteins detected by immunohistochemistry from patients with cancer of the central nervous system (n  11 patients) and
liver-pancreas (n  17 patients). (B) Example of immunohistochemistry of CIRP and P-ERK1/2 proteins in the tumor from a patient with liver
cancer.
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S6, 4E-BP1, and eIF-4s have a fundamental role in transla-
tional control and the ultimate stimulation of protein synthesis.
This is a result of their involvement in cap-dependent mRNA
translation, which accounts for the synthesis of the vast major-
ity of cellular proteins (all mRNAs transcribed in the nucleus
bear a 5 cap). S6 phosphorylation has been linked to an
increase in the initiation of translation. In contrast to the
activation caused by S6 phosphorylation, 4E-BP1 phosphory-
lation produces an inactive protein that releases other tran-
scription factors responsible for initiating translation (29).
Interestingly, we found that the phosphorylation levels of
both S6 ribosomal and 4E-BP1 proteins were increased in
CIRP MEFs compared to GFP MEFs. Based on these data, we
propose that the principal mechanism used by CIRP to im-
mortalize cells is the activation of general protein synthesis.
This is achieved through the phosphorylation of S6 ribosomal
protein, which increases the ratio of P-4E-BP1 to total 4E-BP1
through ERK1/2. Specific phosphorylation of ribosomal pro-
tein S6 and 4E-BP1 has been linked mechanistically to in-
creases in translational efficiency in response to a variety of
growth-inducing stimuli (39). Specific phosphorylation at po-
sitions 235 and 236 in S6 and positions 37 and 46 in 4E-BP1
would explain the general increase in protein synthesis ob-
served in CIRP MEFs. As expected in the senescent status of
K-rasVal12 MEFs, we found a downregulation of S6 phosphor-
ylation at positions 240 and 244 and a downregulation of P-4E-
BP1. From these studies, we could not rule out the possibility
of a direct/indirect interaction of CIRP with proteins involved
in the transcriptional machinery. However, S6 and 4E-BP1
activation would seem to be a more important mechanism than
c-fos activation in the mediation of CIRP immortalization. The
fact that c-fos protein, unlike P-S6 and P-4E-BP1, does not
decrease upon treatment of CIRP-expressing MEFs with the
MEK inhibitor PD98058 supports this proposal.
In agreement with our previous data, it is important to note
that CIRP inhibition decreases proliferation in not only CIRP
MEFs but also HeLa cancer cells and the ES cell-derived
TERA cell line. The P-ERK1/2 status is specifically compro-
mised in MEFs but not in the other cancer cell types tested
(Fig. 3B and D and 5B; also data not shown). Although CIRP
siRNAs decrease cell number in these cancer cell lines, CIRP
inhibition might affect different target proteins. The fact that
P-ERK1/2 status is not compromised in HeLa or TERA cells
when CIRP is inhibited could be due to the ability of cancer
cells to activate simultaneously multiple growth-promoting
pathways in order to fully transform (12). Under these circum-
stances, inhibition of one proliferation-promoting pathway
would not compromise proliferation since the other pathways
could maintain the proliferative status. For example, human
colorectal cancer cells harboring a BRAF(V600E) mutation
are growth factor independent for the activation of ERK1/2
and survival (58). Given the fact that CIRP is an RNA-binding
protein involved in several biological processes (7), its ability to
act on different targets might differ in a cell context-dependent
manner.
Three concepts led us to hypothesize that CIRP may be
relevant in human cancer. (i) ERK1/2 activity potentially has a
prognostic value in patient outcome (33). (ii) Total 4E-BP1 is
potentially overexpressed in high-grade (compared to low-
grade) human tumors, and nearly all the 4E-BP1 proteins are
FIG. 9. Proposed model to explain why CIRP and K-rasVal12 genes evolve into different cell responses upon activation with the same MAPK
cascade. In CIRP-expressing MEFs, the proliferative signals driven mainly by P-S6, P-4E-BP1, and c-fos activate cyclin D1 and its associated kinase
activity. Although the same MAPK pathway is activated in K-rasVal12 MEFs, major inhibitory signals are present that are driven by the proteins
p19ARF, p21WAF1, and p16INK4a. These proteins dictate a different cell fate.
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phosphorylated (1, 43). (iii) In accordance with these two facts,
we observed that the phosphorylation status of ERK1/2 and
4E-BP1 is upregulated in CIRP MEFs.
A subgroup of colon (33%) and prostate (36%) cancers
showed upregulated CIRP mRNA in tumor cells compared to
normal tissue. This finding suggests that CIRP upregulation
may have biological significance in human tumors. Our results
disagree with a previous study by Hamid et al. in which CIRP
expression was reported to decrease in tumor tissue (14). Dif-
ferences between the results of that study and ours may be
related to the type of cancer analyzed and to the methodology
used in our series of colon and prostate cancers. In order to
validate CIRP expression in a myriad of samples, a compre-
hensive study of the CIRP protein in several tumor types was
performed in a total of 193 patients. CIRP and P-ERK1/2
proteins were found to be expressed in 28% and 23%, respec-
tively, of the patients analyzed. Interestingly, CIRP expression
was associated with P-ERK1/2 in a group of patients with
tumors derived from the central nervous system (P  0.05).
Moreover, a tendency toward significance was observed in
some patients with liver-pancreas carcinomas (P  0.08).
The decrease in growth rate found in mammalian cells
treated with mild cold stress is not entirely attributable to
arrested metabolism. This decrease may also involve an active
process in which CIRP and other stress-responsive proteins
(e.g., Rbm3 [9]) play a fundamental role in stimulating prolif-
eration. We hypothesize that although most cell proteins are
downregulated or inhibited with cold stress, CIRP is activated.
CIRP shuts down a signal, thereby maintaining cells in an
active proliferative status. Although the external temperature
under mild cold stress may not be the most appropriate, it is
not so unbearable that cell growth would be stopped. In this
report, we describe for the first time that CIRP bypasses rep-
licative senescence when overexpressed at a physiological tem-
perature (37°C). This bypass is achieved through ERK1/2 ac-
tivation in MEFs. The mechanisms are similar, but not
identical, to those occurring in K-rasVal12 overexpression. It
should be noted that these results indicate that CIRP may
operate in a different manner than K-rasVal12 (which may be
ERK1/2 independent).
Senescence is an integrated response to diverse signals. In
this study, we showed that ERK1/2 activation in primary cells
does not necessarily involve premature entry into senes-
cence—it can also promote proliferation. Premature entry into
senescence has been previously described, but proliferation has
not (24, 61). From our results, we conclude that CIRP bypasses
senescence by ultimately upregulating cyclin D1. Cyclin D1
stimulates an increase in cyclin D1-CDK4 kinase activity
through the MAPK pathway and proteins involved in the ini-
tiation of translation. We propose a comparative model be-
tween CIRP and K-rasVal12 explaining why CIRP MEFs bypass
senescence and K-rasVal12 MEFs enter it (Fig. 9). Our data
suggest that different cell responses are shut down depending
on P-ERK1/2 levels. Therefore, ERK1/2 activation must be
finely tuned by the cell to allow for the most appropriate
response.
Insight into the molecular mechanisms that control ES cell
growth will help us understand how cancer cells become im-
mortalized. CIRP and other RNA-binding proteins should be
further studied to elucidate their interaction with mRNAs in
cell signaling, senescence, and human tumors.
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